What is the clinical evidence from this study?

Study design: Letter. Population: SARS-CoV-2 infection (n=118). Intervention: Anti-spike (S) antibodies vs. Anti-nucleocapsid (N) antibodies. Primary outcome: Seropositivity at 7-10 months (p=<.01).

What does this research mean for the field?

The half-life of SARS-CoV-2 anti-spike antibodies is more than double that of anti-nucleocapsid antibodies, resulting in significantly higher long-term seropositivity at 7–10 months post-infection (92.4% vs 17.8%). Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

March 5, 2021Clinical Infectious DiseasesOpen Access

Estimated Half-Life of SARS-CoV-2 Anti-Spike Antibodies More Than Double the Half-Life of Anti-nucleocapsid Antibodies in Healthcare Workers

Q: What are the key findings of this study?

Anti-spike antibodies maintained seropositivity at 7-10 months in 92.4% of healthcare workers compared to 17.8% for anti-nucleocapsid antibodies, with an estimated half-life of 198.8 vs 76.4 days.

Q: What does this research mean for the field?

The half-life of SARS-CoV-2 anti-spike antibodies is more than double that of anti-nucleocapsid antibodies, resulting in significantly higher long-term seropositivity at 7–10 months post-infection (92.4% vs 17.8%). Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

View Full Paper

Ask AI

Bookmark

Key result

Anti-spike antibodies maintain seropositivity in ~92% of healthcare workers at seven to ten months, outlasting anti-nucleocapsid antibodies.

P<.01
n=118

Why the study?

It was unclear whether longer anti-spike antibody responses compared to anti-nucleocapsid responses were due to slower waning or higher initial antibody levels.

Population

118 healthcare workers with previous SARS-CoV-2 infection

Comparison

Anti-S vs anti-N antibody levels and waning

Design

Observational cohort study

Follow-up

7–10 months

Authors

JEJan Van ElslandeRenson (Belgium)LGLien Gruwier LGLode GodderisEuropean External Action Service

Discussion

Member takes

Implication

Anti-spike serology may better track prior infection in HCWs; leaves open durability of protective immunity.

Structured PICO

Population

118 healthcare workers (median age 48, 88.1% women) with previous mild SARS-CoV-2 infection, sampled 1-3 months and 7-10 months after positive PCR.

Outcome

Estimated half-life of SARS-CoV-2 IgG anti-nucleocapsid (anti-N) and anti-spike (anti-S) antibodiessurrogate

Main Result

Absolute Event Rate: 92.4% vs 17.8%

p-value: p=<.01

SARS-CoV-2 anti-spike antibodies have a significantly longer half-life (198.8 days) compared to anti-nucleocapsid antibodies (76.4 days) in healthcare workers with mostly mild COVID-19.

Cite This Study

Elslande et al. (2021) conducted a letter in SARS-CoV-2 infection (n=118). Anti-spike (S) antibodies vs. Anti-nucleocapsid (N) antibodies was evaluated on Seropositivity at 7-10 months (p=<.01). Anti-spike antibodies maintained seropositivity at 7-10 months in 92.4% of healthcare workers compared to 17.8% for anti-nucleocapsid antibodies, with an estimated half-life of 198.8 vs 76.4 days.

synapsesocial.com/papers/6aa94aa5c924504423cdce16 https://doi.org/10.1093/cid/ciab219

View Full Paper

Ask AI

Bookmark

Estimated Half-Life of SARS-CoV-2 Anti-Spike Antibodies More Than Double the Half-Life of Anti-nucleocapsid Antibodies in Healthcare Workers

Discussion

Member takes

Implication

Structured PICO

Main Result

Cite This Study

Estimated Half-Life of SARS-CoV-2 Anti-Spike Antibodies More Than Double the Half-Life of Anti-nucleocapsid Antibodies in Healthcare Workers

Discussion

Member takes

Implication

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider